Nutritional Management of Patients with Fatty Acid Oxidation Disorders.

Fecha de publicación: 14/08/2024 Fecha Ahead of Print: 14/08/2024

Autores de IIS La Fe

• Patricia Correcher Medina

  Autor

Participantes ajenos a IIS La Fe

• Pena-Quintana, Luis

Grupos

• Nutrición y Metabolopatías

  Investigador Principal

  Patricia Correcher Medina

• Perinatología

  

  Leader

  Máximo Vento Torres

Abstract

Treatment of fatty acid oxidation disorders is based on dietary, pharmacological and metabolic decompensation measures. It is essential to provide the patient with sufficient glucose to prevent lipolysis and to avoid the use of fatty acids as fuel as far as possible. Dietary management consists of preventing periods of fasting and restricting fat intake by increasing carbohydrate intake, while maintaining an adequate and uninterrupted caloric intake. In long-chain deficits, long-chain triglyceride restriction should be 10% of total energy, with linoleic acid and linolenic acid intake of 3-4% and 0.5-1% (5/1-10/1 ratio), with medium-chain triglyceride supplementation at 10-25% of total energy (total MCT+LCT ratio = 20-35%). Trihepatnoin is a new therapeutic option with a good safety and efficacy profile. Patients at risk of rhabdomyolysis should ingest MCT or carbohydrates or a combination of both 20 min before exercise. In medium- and short-chain deficits, dietary modifications are not advised (except during exacerbations), with MCT contraindicated and slow sugars recommended 20 min before any significant physical exertion. Parents should be alerted to the need to increase the amount and frequency of carbohydrate intake in stressful situations. The main measure in emergency hospital treatment is the administration of IV glucose. The use of carnitine remains controversial and new therapeutic options are under investigation.

Keywords

• cardiomyopathy; energy metabolism; fatty acid oxidation; fatty acid oxidation disorders; hypoglycaemia; inborn errors of metabolism; intrahepatic lipids; myopathy; rhabdomyolysis; triheptanoin